NSE filing, NSE: BALAXI. Summary written from the filing by ALFA Finder's alert engine.
Balaxi Pharmaceuticals Ltd: key numbers
- Share price
- ₹19.15
- Market cap
- ₹105.7 Cr
- Revenue (annual)
- ₹270.2 Cr
- Net profit (annual)
- ₹1.42 Cr
- P/E (TTM)
- 43.6×Sector 45.9×
- Promoter holding
- 65.99%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Balaxi Pharmaceuticals Ltd
All →Balaxi Pharmaceuticals Board Meeting Date
Balaxi Pharmaceuticals will meet on 12 November 2026 to approve unaudited half-year results. The trading window stays closed until 14 November 2026.
Balaxi Pharmaceuticals Other Announcement
Balaxi Pharmaceuticals Limited reported nil activity regarding the re-lodgement of physical share transfer requests for the period ended September 2026.
Balaxi Pharmaceuticals Business Update
Balaxi Pharmaceuticals has received WHO-GMP certification for its first pharmaceutical formulation manufacturing facility in Telangana. The facility has commenced manufacturing initially approved products for international markets.
Balaxi Pharmaceuticals Management Change
Balaxi Pharmaceuticals Limited shareholders approved the re-appointment of Ms. Akshita Ostwal as an Independent Director for a second five-year term starting September 5, 2026.
Balaxi Pharmaceuticals Annual General Meeting
Balaxi Pharmaceuticals Limited held its 83rd Annual General Meeting on August 24, 2026. Shareholders voted on financial statements and director re-appointments during the proceedings.
Balaxi Pharmaceuticals Investor Presentation: Key Takeaways
Balaxi reported 14.1% YoY revenue growth in Q1 FY27, driven by market diversification and its first proprietary manufacturing facility. Strategy emphasizes backward integration in Latin America and Africa.
Other other announcement announcements
All →Juniper Green Energy Other Announcement
Juniper Green Energy filed CARE Ratings' monitoring agency report for the quarter ended September 2026. Report confirms IPO proceeds used as per offer document, with no deviations.
Bright Outdoor Media Other Announcement
Bright Outdoor Media Ltd filed its half-yearly shareholding pattern for the period ended September 30, 2026. This is a routine SEBI Reg 31 holding statement with no transaction or business event.
Munoth Communication Other Announcement
Munoth Communication filed its quarterly shareholding pattern for the quarter ended September 30, 2026. The filing is a routine periodic disclosure with no transaction.
Purple Style Labs Other Announcement
Purple Style Labs Limited (unlisted) filed its quarterly shareholding pattern for the quarter ended 30 September 2026 under Regulation 31(1)(b). It is a routine periodic disclosure with no transaction or money involved.
Chemkart India Other Announcement
Chemkart India reported no IPO fund deviation for the half year ended 30 September 2026. Rs.39.48 Crore of Rs.64.47 Crore allocation is utilised.
Zee Entertainment Enterprises Other Announcement
Zee Entertainment updated its authorised KMP list for Reg 30 disclosures, effective 2 November 2026, after a Company Secretary change. No money or business event is involved.